PAIN interrupted,
LIFE transformed

Complex Regional Pain Syndrome (CRPS)?
See if DRG therapy is right for you.

Complex Regional Pain Syndrome (CRPS) is a chronic condition that causes intense pain, often in the lower body (such as the foot, ankle, knee, leg, or hip). CRPS typically develops after an injury or surgery – however, the pain associated with CRPS is usually much greater than the original injury.

Symptoms of CRPS include:

  • Intense burning pain
  • Changes in skin temperature, color, or texture
  • Extreme skin sensitivity
  • Swelling or stiffness in the affected area

If you’re living with CRPS pain, you may be a candidate for DRG therapy – a new, non-drug approach to pain relief currently being offered at select pain treatment centers through the TARGET Clinical Study.

What is DRG Therapy?

Neurostimulaton is a non-drug option for treating chronic pain that uses a small implanted device called a “neurostimulator.” The neurostimulator delivers mild electrical pulses to the nerves in your spinal cord – replacing the original pain signal with a tingling or massaging feeling, covering the specific area where you feel pain. FDA-approved neurostimulators have been used to treat over 300,000 chronic pain sufferers.


DRG therapy is a new form of neurostimulation that targets a specific cluster of nerves in the spine called the Dorsal Root Ganglion (DRG). The DRG acts like a traffic light, regulating signals and sensations as they travel to the brain. Stimulation of the DRG can actually modify the pain signals getting through – thereby reducing pain. Like other neurostimulation systems, DRG therapy comes with a handheld “remote control” that lets you adjust the strength and location of stimulation, or even turn stimulation off.


One benefit of DRG therapy is that you can try it for a period of time (typically 3 - 12 days) before you have it implanted. The temporary DRG system is placed through a short, outpatient procedure and is completely reversible. Your doctor will place thin wires, called leads, in your back. The leads connect to a temporary device you can wear outside of your clothing. If after the trial period you are satisfied with your pain relief, you can choose to have the system implanted. This is done through another short, reversible surgical procedure to place the neurostimulator beneath the skin.



The TARGET Study

If you’re living with CRPS pain affecting the lower body (such as the foot, ankle, knee, leg, or hip), you may be a candidate for DRG therapy – a new, non-drug approach to pain relief currently being offered at select pain treatment centers through the TARGET Clinical Study. DRG therapy is FDA-approved for the treatment of CRPS pain affecting the lower limbs, and this study will help gather additional information about this new therapy.

As a participant in the TARGET Study, you will be asked to visit your local study center 4 times over a 12-month period after receiving your DRG system. During these visits, your study doctor will ask about how you are feeling, check your DRG system, and have you complete a few questionnaires to document your experiences. You may also be reimbursed for your time and travel to attend these visits.



Frequent Questions
Neurostimulation is a well-established therapy for treating chronic pain. FDA-approved neurostimulator systems have been used to treat over 300,000 chronic pain sufferers.
Yes, DRG therapy is FDA-approved for the treatment of chronic lower limb pain resulting from Complex Regional Pain Syndrome (CRPS).
In the largest neurostimulation clinical trial ever conducted for patients with chronic lower limb pain resulting from a previous injury, DRG patients had an average 81.4% reduction in their pain at 12 months.*
People describe the sensation differently. Some people describe DRG therapy as a tingling or massaging feeling over the painful area. Others have reported that they simply feel the absence of pain. Your study doctor will be able to discuss these and other experiences with you.
Yes, the handheld remote control allows you to adjust the strength and location of stimulation, or turn the stimulation off.
About 375 people will participate in the TARGET Study at approximately 40 pain treatment centers throughout the U.S.
Following implantation of your DRG system, you will return to your study doctor’s office 4 times over the next 12 months. During these visits, your study doctor will ask about how you are feeling, check your DRG system, and have you complete a few questionnaires to document your experiences.
To see if you might qualify for the TARGET Study, and to get connected with your local study center to learn more, the next step is taking the pre-screening questionnaire. Please click here to get started.

* Levy, R. & Deer, T. (2015). A prospective, randomized, multi-center controlled clinical trial to assess the safety and efficacy of the Spinal Modulation Axium Neurostimulator System in the treatment of chronic pain. Presented at NANS 2015.

See If You Qualify

To see if you might qualify for the TARGET Study, and to get connected with the study center in your area to learn more, please complete the questionnaire below.